|
|
 |
|
By Principal Investigator:
U V W X Y Z
| Principal Investigator |
Title |
IRB#: |
| Vichinsky, Elliott MD |
Secondary Hemochromatosis in B-Thalassemia and Sickle Cell Disease |
1999-026 |
| Vichinsky, Elliott MD |
Cellular Mechanisms for Iron Storage in B Thalassemia and Sickle Cell Disease and Correlation with Oxidative Injury |
2000-026 |
| Vichinsky, Elliott MD |
Thalasemmia Clinical Research Network Registry |
2001-023 |
| Vichinsky, Elliott MD |
Thalassemia Clinical Research Network Hepatitis C Clinical Trial |
2003-010 |
| Vichinsky, Elliott MD |
A Pilot Study of the Response of Oxidant Stress Induced Injury and Mitochondrial Dysfunction Biomarkers to Treatment with Iron Chelators: Ancillary Study of the Novartis ICL670 107 Open Label Phase III Trial |
2003-011 |
| Vichinsky, Elliott MD |
A 3-Year Extension to a Multi-Center, Open-Label, Non-Comparative, Phase II Trial on Efficacy and Safety of ICL670 (5 to 40 mg/kg/day) Given for at Least 1 Year to Patients with Chronic Anemias and Transfusional Hemosiderosis (ICL670 108E) |
2004-063 |
| Vichinsky, Elliott MD |
Neuropsychological Dysfunction and Neuroimaging Abnormalities in Neurologically Intact Adults with Sickle Cell Disease |
2004-081 |
| Vichinsky, Elliott MD |
A One Year Open-Label , Non-Comparative Extension to a Randomized, Multicenter, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and the Effects on Liver Iron Concentration of Repeated Doses of 5-30 mg/kg/day of ICL670 Relative to Def |
2005-003 |
| Vichinsky, Elliott MD |
The Compassionate Use of Ferriprox (Deferiprone) in Patients with Transfusion Dependent Anemia and Chronic Iron Overload (Apotex Inc.) |
2005-087 |
| Vichinsky, Elliott MD |
Epidemiology of Priapism |
2005-090 |
| Vichinsky, Elliott MD |
The Collaborative Data Project |
2006-007 |
| Vichinsky, Elliott MD |
A Longitudinal Cohort Study of Patients with Thalassemia in the Thalassemia Clinical Research Network |
2006-073 |
| Vichinsky, Elliott MD |
A 5 Year Observational Study (registry) of Children Aged 2 to <6 Years at Enrollemnt with Hemosiderosis Treated with Deferasirox |
2007-017 |
| Vichinsky, Elliott MD |
Safety of Deferasirox (ICL670) and Deferocamine (Desferal or DFO) Combined Chelation Therapy in Patients with Transfusion Dependent Thalassemia and Ironoverload |
2007-040 |
| Vichinsky, Elliott MD |
A Phase IIA study of subcutaneous 5-AZA-2’-deoxycytidine (Decitabine) in patients with Thalassemia Intermedia |
2008-048 |
| Vichinsky, Elliott MD |
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study To Evaluate Efficacy And Safety Of Deferasirox In Non-Transfusion-Dependent Thalassemia Patients With Iron Overload (CICL670A2209) |
2008-084 |
| Vichinsky, Elliott MD |
A Single-Arm, Open-Label Study Of The Palatability And Tolerability Of Exjade Taken With Meals, With Different Liquids Or Crushed And Added To Food |
2008-085 |
| Vichinsky, Elliott MD |
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 in Subjects with Sickle Cell Disease (SCD) - Protocol # HQP 2008-004 |
2009-006 |
| Viteri, Fernando MD, PhD |
Determination of Folate Levels in Density Fractionated Human Erythrocytes & In Vitro Kinetics of Folate Uptake / Efflux by Purified Red Blood Cells |
2007-035 |
| Viteri, Fernando MD, PhD |
Effectiveness of NaFeEDTA and FeSO4 on Inhibiting Lead Absorption |
2008-035 |
| Wachtel, Renee MD |
Rett Syndrome Natural History |
2005-085 |
| Wachtel, Renee MD |
An Open-Label Study to Evaluate the Safety of Donepezil Hydrochloride (Aricept®) for up to 1 Year in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome - Follow-Up to a 10 Week, Double-Blind, Placebo-Controlled Trial (A2501060) |
2008-040 |
| Wachtel, Renee MD |
Markers of Autism Risk in Babies--Learning Early Signs (MARBLES) |
2008-083 |
| Walters, Mark MD |
Allogeneic Marrow Transplantation from HLA-Identical Related Donors for Treatment of Homozygous Thalassemia Major and other Red Cell Disease (Excluding Sickle Cell Anemia) Activation Date 6/23/93 |
2000-005 |
| Walters, Mark MD |
Pilot Study of High Dose Chemotherapy with Busulfan, Melphalan and Topotecan with Peripheral Blood Stem Cell Rescue in Advanced Stage and Recurrent Tumors |
2002-050 |
| Walters, Mark MD |
International Bone Marrow Registry/Autologous Blood & Marrow Transplant Registry (IBMTR/ABMTR) |
2002-077 |
| Walters, Mark MD |
Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation from HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Study (2054.00-FH) |
2006-046 |
| Walters, Mark MD |
Soluble Tumor Necrosis Factor Receptor: Enbrel® (Etanercept) for the Treatment of Acute, Non-infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation. ASCT0521 |
2006-091 |
| Walters, Mark MD |
Hematopoietic Cell Transplantation for Treatment of Patients with Primary immunodeficiencies and other Nonmalignant Inherited Disorders using low-dose TBI and Fludarabine with or Without Campath®. (2007-FH) |
2007-011 |
| Walters, Mark MD |
A Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Relapsed ALL. COG ASCT0431 (PBMTC ONC051) |
2007-013 |
| Walters, Mark MD |
Multi-Center, Open Label, Randomized Trial Comparing Single versus Double Umbilical Cord Blood Transplantation in Pediatric patients with High Risk Leukemia or Myelodysplasia. (BMT-CTN-0501) |
2007-072 |
| Walters, Mark MD |
Unrelated Donor Hematopoietic Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen-(BMTCTN 0601) |
2008-038 |
| Walters, Mark MD |
A Dose Escalation of Clofarabine in Combination with Cytarabine and Total Body Irradiation Followed by Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia and Non-Lymphoblastic Leukemia (CHNY06-531) |
2008-049 |
| Walters, Mark MD |
The IMPROVE Trial: Improving Pain Management and Outcomes with Various Strategies of Patient-Controlled Analgesia (PCA) |
2009-060 |
| Walters, Mark MD |
Collection of Bone Marrow and Blood from Patients with Genetic Diseases of Blood Cells |
2009-082 |
| Walters, Patrick, Phd |
Dysregulation of the Innate Immune Response in thalassemia major: a Possible Mechanism for Increased Infection Risk |
2008-074 |
| Waterson, John MD PhD |
MPS I Registry Protocol and Patient Information and Authorization for Release of Clinical Information to the MPS I Registry |
2004-096 |
| Waterson, John MD PhD |
National Ophthalmic Genotyping and Phenotyping Network, Stage 1 -- Creation of DNA Repository for Inherited Ophthalmic Diseases |
2009-078 |
| Zlotnick, Cheryl RN DrPH |
The Social Environment of Oakland Teens |
2004-077 |
| Zlotnick, Cheryl RN DrPH |
Health Status and Behaviors of Adults with Histories of Foster Care |
2005-040 |
| Zlotnick, Cheryl RN DrPH |
Substance Abuse, Child Neglect and Homeless Families |
2005-006 |
| Zlotnick, Cheryl RN DrPH |
Health Care provided to the Homeless (HCH) |
2005-095 |
| Zlotnick, Cheryl RN DrPH |
Focus Groups on Successful Parenting |
2006-041 |
| Zlotnick, Cheryl RN DrPH |
Alameda County Healthcare for Homeless Families Assessment |
2008-081 |
| Zuluaga, Maria T. MD |
Use of Brain Near Infrared Spectroscopy (NIRS) in Children with Intracranial Hypertension |
2006-098 |
Revised:
Friday, February 26, 2010 9:11 AM
|
Cholesterol Research Center 
